Tandem Diabetes Care TNDM Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Tandem Diabetes Care’s reported figures.
Based on trailing twelve months.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's return on equity?
- Tandem Diabetes Care (TNDM) reported return on equity of -65.7% in Q1 2026.
- How has Tandem Diabetes Care's return on equity changed year-over-year?
- Tandem Diabetes Care's return on equity increased by 28.8% year-over-year, from -92.3% to -65.7%.
- What is the long-term trend for Tandem Diabetes Care's return on equity?
- Over 5 years (2020 to 2025), Tandem Diabetes Care's return on equity has grown at a 51.5% compound annual growth rate (CAGR), from -12.3% to -97.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.